Tag Archives: clinical trials

Health Policy Updates: April 29 2017

The GOP has finalized a new version of the AHCA, with the goal of getting enough votes from the party membership to ensure passage. The broad structure of the bill appears to remain largely unchanged.

“The GOP’s new proposal would allow states to opt out of many of Obamacare’s requirements, allowing health plans to charge people more based on their age and health status. States could also opt out of enforcing a 30 percent surcharge imposed on people who don’t maintain insurance coverage, which was part of the original GOP proposal, according to a brief update sent to Energy and Commerce members. That’s the policy that the Republicans would use to replace the Obamacare individual mandate…In exchange, states would have to set up a high-risk pool where older, sicker people could buy coverage, likely at much higher prices.”

Apparently, the most-conservative Freedom Caucus members are now starting to support the bill. However, the delay of the proposed House vote yesterday likely means that sufficient GOP support still isn’t there.
Continue reading Health Policy Updates: April 29 2017

Health Policy Updates: May 28 2016

An new public health paper in Health Affairs this week compared the effects of social health spending vs. medical spending on outcomes for several common illnesses such as heart attack and diabetes. The results add credence to the view that the social determinants of health may be more important than the medical system in keeping people health.

“We found that states with a higher ratio of social to health spending (calculated as the sum of social service spending and public health spending divided by the sum of Medicare spending and Medicaid spending) had significantly better subsequent health outcomes…”

Continue reading Health Policy Updates: May 28 2016

Health Policy Updates: May 21 2016

From Margot Sanger-Katz in the New York Times, on why moving to single-payer health care would be unlikely to “fix” the United States’ health care cost problem. Summary: even if you were to cut out our (significant) administrative costs, such a program would still cost more to run than in other countries because the underlying price of health care is so much higher here.

“That Medicare-for-all plan would still cost more than single-payer plans in other countries. Here’s why: Medicare pays doctors and hospitals higher prices than single-payer systems do in other countries.” Continue reading Health Policy Updates: May 21 2016

Health Policy Updates: April 9 2016

Last year, the news-worthy story was that “thousands of women with ovarian cancer are not getting a proven, life-saving treatment.” That treatment, intraperitoneal (IP) chemotherapy had some clinical trials showing that it was much more effective than conventional chemotherapy. The kerfuffle was over the fact that IP chemo was not getting incorporated into medical practice, despite the evidence showing it’s benefit, and too many women were still getting traditional chemo. You can find the NYTimes report on this, here.

One year later, we are also one year wiser. Unfortunately, a newer, better study of IP chemo for ovarian cancer failed to show any benefit. It now looks like IP chemo isn’t any better than regular chemotherapy – and is a lot more grueling to endure. Sometimes, medical science is messy like this. While it is certainly bad that many people have probably gotten this treatment unnecessarily, it is science’s dedication to thorough testing and self-questioning that prevented a far worse outcome – that many thousands of future women would go on receiving IP chemo, on the false understanding that it is beneficial. Continue reading Health Policy Updates: April 9 2016

Health Policy Updates: December 19 2015

The Washington Post’s Wonkblog reports on a new study out of UNC-Chapel Hill, finding that significant out-of-pocket prescription drug costs still exist for seniors on Medicare. Even once the “donut hole” closes, prohibitive coverage gaps for seniors will still exist.

“What the researchers found is that closing the coverage gap will save money – about $2,500 at current cancer drug prices. But that still means around $4,000 to $10,000 out-of-pocket spending for patients, which may be unattainable for people on a fixed income. And that assumes that drug prices stay stable and do not increase, as they’ve been doing for many cancer drugs.” Continue reading Health Policy Updates: December 19 2015